Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic.

Nixon S, Bezverbnaya K, Maganti M, Gullane P, Reedijk M, Kuruvilla J, Prica A, Kridel R, Kukreti V, Bennett S, Rogalla P, Delabie J, Pintilie M, Crump M.

J Oncol Pract. 2019 Oct 1:JOP1900202. doi: 10.1200/JOP.19.00202. [Epub ahead of print]

PMID:
31573831
2.

Pembrolizumab for the treatment of diffuse large B-cell lymphoma.

Sheikh S, Kuruvilla J.

Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28.

PMID:
31456438
3.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492. [Epub ahead of print]

PMID:
31398081
4.

Dermoscopy of Primary Cutaneous Amyloidosis in Skin of Color.

Kaliyadan F, Alkhateeb A, Kuruvilla J, Swaroop K, Alabdulsalam AA.

Dermatol Pract Concept. 2019 Jul 31;9(3):232-234. doi: 10.5826/dpc.0903a17. eCollection 2019 Jul. No abstract available.

5.

PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.

Okuyama K, Strid T, Kuruvilla J, Somasundaram R, Cristobal S, Smith E, Prasad M, Fioretos T, Lilljebjörn H, Soneji S, Lang S, Ungerbäck J, Sigvardsson M.

PLoS Genet. 2019 Aug 5;15(8):e1008280. doi: 10.1371/journal.pgen.1008280. eCollection 2019 Aug.

6.

Optimal management of mantle cell lymphoma in the primary setting.

Tang C, Kuruvilla J.

Expert Rev Hematol. 2019 Sep;12(9):715-721. doi: 10.1080/17474086.2019.1639501. Epub 2019 Jul 19.

PMID:
31268728
7.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.

Vijenthira A, Maganti M, Kukreti V, Kuruvilla J, Tiedemann R, Chen C, Crump M, Prica A.

Leuk Lymphoma. 2019 Oct;60(10):2576-2579. doi: 10.1080/10428194.2019.1585837. Epub 2019 Apr 18. No abstract available.

PMID:
30997853
8.

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1158-1163. doi: 10.1016/j.bbmt.2019.01.014. Epub 2019 Jan 14.

PMID:
30654137
9.

Proteomic Analysis of Endothelial Cells Exposed to Ultrasmall Nanoparticles Reveals Disruption in Paracellular and Transcellular Transport.

Kuruvilla J, Bayat N, Cristobal S.

Proteomics. 2019 Mar;19(5):e1800228. doi: 10.1002/pmic.201800228. Epub 2019 Feb 25.

PMID:
30632670
10.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
11.

Optimal frontline management of mantle cell lymphoma: can we agree?

Tang C, Kuruvilla J.

Expert Rev Hematol. 2018 Dec;11(12):911-914. doi: 10.1080/17474086.2018.1537778. Epub 2018 Nov 5. No abstract available.

PMID:
30336708
12.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE.

Leuk Lymphoma. 2019 Apr;60(4):912-919. doi: 10.1080/10428194.2018.1515937. Epub 2018 Oct 10.

PMID:
30301414
13.

Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Kuruvilla J, Sasmita AO, Ling APK.

Neurol Sci. 2018 Nov;39(11):1827-1835. doi: 10.1007/s10072-018-3521-0. Epub 2018 Aug 3. Review.

PMID:
30076486
14.

Significance of treatment response when managing patients with primary central nervous system lymphoma.

Chan H, Moraes FY, Berlin A, Crump M, Mason W, Laperriere N, Kuruvilla J, Prica A.

Leuk Lymphoma. 2019 Feb;60(2):349-357. doi: 10.1080/10428194.2018.1474524. Epub 2018 Jul 3.

PMID:
29966463
15.

Zinc Finger Protein 521 Regulates Early Hematopoiesis through Cell-Extrinsic Mechanisms in the Bone Marrow Microenvironment.

Fleenor CJ, Arends T, Lei H, Åhsberg J, Okuyama K, Kuruvilla J, Cristobal S, Rabe JL, Pandey A, Danhorn T, Straign D, Espinosa JM, Warming S, Pietras EM, Sigvardsson M, Hagman JR.

Mol Cell Biol. 2018 Aug 15;38(17). pii: e00603-17. doi: 10.1128/MCB.00603-17. Print 2018 Sep 1.

16.

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.

Kuruvilla J, Tzeng CH, Cho SG, Kim SJ, Tang JL, Su Y, Wu J, Vargo R, Cheverton P.

Bone Marrow Transplant. 2019 Feb;54(2):258-264. doi: 10.1038/s41409-018-0253-y. Epub 2018 Jun 12.

17.

Harnessing neuroplasticity: modern approaches and clinical future.

Sasmita AO, Kuruvilla J, Ling APK.

Int J Neurosci. 2018 Nov;128(11):1061-1077. doi: 10.1080/00207454.2018.1466781. Epub 2018 May 4. Review.

PMID:
29667473
18.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.

19.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

20.

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review.

Mayo SJ, Kuruvilla J, Laister RC, Ayala AP, Alm M, Byker W, Kelly DL, Saligan L.

BMJ Open. 2018 Jan 27;8(1):e017578. doi: 10.1136/bmjopen-2017-017578. Review.

21.

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J.

Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.

PMID:
29276022
22.

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.

Falcone U, Jiang H, Bashir S, Tsang R, Kukreti V, Keating A, Crump M, Kuruvilla J.

Bone Marrow Transplant. 2018 Mar;53(3):347-351. doi: 10.1038/s41409-017-0054-8. Epub 2017 Dec 21. No abstract available.

PMID:
29269808
23.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.

Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764.

PMID:
29253068
24.

Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.

Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Viswabandya A, Messner HA, Michelis FV.

Eur J Haematol. 2018 Feb;100(2):198-205. doi: 10.1111/ejh.13000. Epub 2017 Dec 13.

PMID:
29168234
25.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA.

Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.

26.

Overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in endothelial cells accelerates coronary artery disease in a mouse model of familial hypercholesterolemia.

Romanelli F, Corbo A, Salehi M, Yadav MC, Salman S, Petrosian D, Rashidbaigi OJ, Chait J, Kuruvilla J, Plummer M, Radichev I, Margulies KB, Gerdes AM, Pinkerton AB, Millán JL, Savinov AY, Savinova OV.

PLoS One. 2017 Oct 12;12(10):e0186426. doi: 10.1371/journal.pone.0186426. eCollection 2017.

27.

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.

Bhimji A, Bhaskaran A, Singer LG, Kumar D, Humar A, Pavan R, Lipton J, Kuruvilla J, Schuh A, Yee K, Minden MD, Schimmer A, Rotstein C, Keshavjee S, Mazzulli T, Husain S.

Clin Microbiol Infect. 2018 Jun;24(6):640-645. doi: 10.1016/j.cmi.2017.09.018. Epub 2017 Sep 29.

28.

Autologous hematopoietic cell transplantation of mantle cell lymphoma: emerging trends.

Falcone U, Kuruvilla J.

Curr Opin Hematol. 2017 Nov;24(6):502-508. doi: 10.1097/MOH.0000000000000383. Review.

PMID:
28832354
29.

Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.

Jain MD, Kuruvilla J.

Drugs. 2017 Oct;77(15):1645-1655. doi: 10.1007/s40265-017-0796-z. Review.

PMID:
28819821
30.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.

Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588.

31.

Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.

Bourlon C, Lipton JH, Deotare U, Gupta V, Kim DD, Kuruvilla J, Viswabandya A, Thyagu S, Messner HA, Michelis FV.

Eur J Haematol. 2017 Sep;99(3):234-239. doi: 10.1111/ejh.12909. Epub 2017 Jun 23.

PMID:
28556258
32.

Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.

Sun HL, Atenafu EG, Tsang R, Kukreti V, Marras TK, Crump M, Kuruvilla J.

Leuk Lymphoma. 2017 Nov;58(11):2607-2614. doi: 10.1080/10428194.2017.1307980. Epub 2017 May 15.

PMID:
28504035
33.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.

Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE.

Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15.

PMID:
28504033
34.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P.

Blood. 2017 Jul 20;130(3):267-270. doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.

35.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M.

Blood. 2017 Jun 15;129(24):3175-3183. doi: 10.1182/blood-2016-11-750174. Epub 2017 May 3.

PMID:
28468797
36.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

37.

Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

Michelis FV, Kotchetkov R, Grunwald RM, Azeem A, Atenafu EG, Lipton JH, Loach D, Gupta V, Kuruvilla J, Kim DD, Viswabandya A, Deotare U, Messner HA.

Biol Blood Marrow Transplant. 2017 Jun;23(6):945-951. doi: 10.1016/j.bbmt.2017.02.015. Epub 2017 Feb 27.

38.

Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.

Moon JH, Hamad N, Sohn SK, Uhm J, Alam N, Gupta V, Lipton JH, Messner HA, Seftel M, Kuruvilla J, Kim DD.

Ann Hematol. 2017 May;96(5):805-815. doi: 10.1007/s00277-017-2939-4. Epub 2017 Feb 18.

PMID:
28214979
39.

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

Kalac M, Lue JK, Lichtenstein E, Turenne I, Rojas C, Amengual JE, Sawas A, Deng C, Mapara MY, Connors JM, Kuruvilla J, O'Connor OA.

Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16. No abstract available.

PMID:
27984643
40.

Gamma Delta T Cell Subset V Gamma 2+ Expansion Associated with Longterm Infliximab Treatment in a Patient with Ankylosing Spondylitis.

Gracey E, Qaiyum Z, Kuruvilla J, Inman RD.

J Rheumatol. 2016 Nov;43(11):2079-2082. No abstract available. Erratum in: J Rheumatol. 2019 Jan;46(1):119.

PMID:
27803350
41.

Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.

Sibai H, Falcone U, Deotare U, Michelis FV, Uhm J, Gupta V, Kuruvilla J, Lipton JH, Seftel MD, Messner HA, Kim DDH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2270-2275. doi: 10.1016/j.bbmt.2016.08.030. Epub 2016 Sep 3.

42.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE.

Leuk Lymphoma. 2017 Jun;58(6):1358-1365. doi: 10.1080/10428194.2016.1239259. Epub 2016 Oct 17.

PMID:
27750483
43.

Post-vomiting purpura.

Kaliyadan F, Kuruvilla JP.

Indian Dermatol Online J. 2016 Sep-Oct;7(5):456-457. No abstract available.

44.

Scanning Electron Microscopy Study of Hair Shaft Damage Secondary to Cosmetic Treatments of the Hair.

Kaliyadan F, Gosai BB, Al Melhim WN, Feroze K, Qureshi HA, Ibrahim S, Kuruvilla J.

Int J Trichology. 2016 Apr-Jun;8(2):94-8. doi: 10.4103/0974-7753.188035.

45.

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A.

Curr Oncol. 2016 Aug;23(4):e409-30. doi: 10.3747/co.23.3137. Epub 2016 Aug 12.

46.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

47.

Using transparent adhesive tape to prevent cross infection during contact dermoscopy.

Kaliyadan F, Kuruvilla J.

Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):744. doi: 10.4103/0378-6323.185046. No abstract available.

48.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH.

J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467.

49.

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>.

Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M.

Leuk Lymphoma. 2017 Jan;58(1):64-69. Epub 2016 Jun 7.

PMID:
27266754
50.

Krüppel-like Factor 4 Modulates Development of BMI1(+) Intestinal Stem Cell-Derived Lineage Following γ-Radiation-Induced Gut Injury in Mice.

Kuruvilla JG, Kim CK, Ghaleb AM, Bialkowska AB, Kuo CJ, Yang VW.

Stem Cell Reports. 2016 Jun 14;6(6):815-824. doi: 10.1016/j.stemcr.2016.04.014. Epub 2016 May 26.

Supplemental Content

Loading ...
Support Center